- Written by senior healthcare analyst for industry dynamics, Michael Leibfried, and lead healthcare analyst for cardiovascular, metabolic and immunological disorders, Jim Coutcher.
GlaxoSmithKline (GSK), the British pharmaceutical giant, acquired Human Genome Sciences (HGS) on Monday, July 16, 2012 for $14.25/share. On an equity basis this deal was worth about $3.6 billion; however, the final deal size was approximately $3 billion net of cash and debt. GSK paid a premium of 99% from when it offered its initial private offering of $13/share in April. HGS was trading at $7.17/share prior to that. GSK believes they will be able to realize $200 million in cost synergies from the deal.